2014
DOI: 10.1159/000367850
|View full text |Cite
|
Sign up to set email alerts
|

The Status of Neuroendocrine Tumor Imaging: From Darkness to Light?

Abstract: Diagnostic imaging plays a pivotal role in the diagnosis, staging, treatment selection and follow-up for neuroendocrine tumors. The available diagnostic strategies are morphologic imaging, including computed tomography, magnetic resonance imaging (MRI) and ultrasound techniques, and molecular imaging, including scintigraphy with 111In-pentetreotide and positron emission tomography with 68Ga-DOTA-peptides, 18F-DOPA and 11C-5-HTP. A combination of anatomic and function… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
60
0
3

Year Published

2014
2014
2024
2024

Publication Types

Select...
5
2
2

Relationship

2
7

Authors

Journals

citations
Cited by 97 publications
(64 citation statements)
references
References 120 publications
(156 reference statements)
1
60
0
3
Order By: Relevance
“…SSR imaging is used for staging and restaging and to select patients for peptide receptor radionuclide therapy (PRRT) with cold or radiolabeled SSAs (17,18). The rationale for SSR imaging is the tumor cell receptor-mediated internalization of the receptorradio-analog complex and its retention in the cytoplasm.…”
Section: Classificationmentioning
confidence: 99%
“…SSR imaging is used for staging and restaging and to select patients for peptide receptor radionuclide therapy (PRRT) with cold or radiolabeled SSAs (17,18). The rationale for SSR imaging is the tumor cell receptor-mediated internalization of the receptorradio-analog complex and its retention in the cytoplasm.…”
Section: Classificationmentioning
confidence: 99%
“…68 Ga-sstr-PET/CT in combination with diffusion-weighted magnetic resonance imaging (DW-MRI) is currently the most promising technique for investigating NETs. The calculated sensitivity from pooled data of 52 studies was highest for sstr-PET compared to endoscopic or intraoperative ultrasound, sstr-scintigraphy, dual-phase (DP)-CT, DW-MRI, and 18 F-FDG-PET, according to a recent extensive review by Bodei et al [5]. In a small number of patients, other molecular PET tracers such as 18 F-DOPA, 11 C-5-HTP [6] or the 68 Ga-exendin-4 targeting glucagon-like peptide-1 (GLP-1) [7] receptor tracer may locate a lesion when sstr-PET/CT is negative.…”
Section: Pancreas Imaging Modalitiesmentioning
confidence: 99%
“…A key unmet need is the necessity to predict future neoplastic behavior (or prognosis) since the alternative is overtreatment (in the case of gastric NETs, antrectomy or in rectal NETs, anterior resection) or repetitive imaging lacking in adequate discriminant ability to identify early progression [4]. Alternatively, developing the ability to predict progress or metastasis provides an opportunity to increase the window of effective therapeutic opportunity, which is a critical issue in NET disease.…”
Section: The Utility Of Biomarkers For Screeningmentioning
confidence: 99%
“…Similarly, in individuals with gastrointestinal stromal tumors treated with imatinib (Gleevec), a therapeutic response can be identified within days using 18 F-FDG PET imaging [3]. In NET disease an analogous protocol, somatostatin receptor imaging (and immunohistochemistry), is useful in the prediction of tumor response to somatostatin analogs and/or targeted peptide receptor radiotherapy [4]. The use of biomarkers or molecular imaging, either alone or in concert, can therefore indicate treatment efficacy, enabling rapid cessation of ineffectual therapies in favor of other potentially effective treatments.…”
Section: Introductionmentioning
confidence: 99%